Ebadi Erfane, Rahimi Maryam, Hosseini Sahar, Mazloomi Maryam, Jamshidnezhad Niousha, Jayervand Fatemeh
Shahid AkbarAbadi Clinical Research Development Unit (SHACRDU) School of Medicine, Iran University of Medical Sciences Tehran Iran.
Firoozabadi Clinical Research Unit (FACRU) School of Medicine, Iran University of Medical Sciences Tehran Iran.
Health Sci Rep. 2025 May 5;8(5):e70817. doi: 10.1002/hsr2.70817. eCollection 2025 May.
The recommended dosing regimens for oral misoprostol in labor induction include 25 μg every 2 h and 50 μg every 4 h. However, there is no specific protocol for these regimens at Shahid Akbarabadi Hospital. This study aimed to assess the safety and effectiveness of the two dosing protocols for labor induction in women with premature rupture of membranes (PROM) and establish a tailored protocol to minimize maternal and neonatal complications.
This randomized controlled trial was conducted at Shahid Akbarabadi Hospital from 2021 to 2023, including pregnant women with term singleton pregnancies and confirmed PROM. Participants were randomly assigned to receive either 25 μg of oral misoprostol every 2 h (up to 12 doses) or 50 μg every 4 h (up to 6 doses). The primary outcome was the mode of delivery. Secondary outcomes included induction-to-delivery time, uterine tachysystole, postpartum hemorrhage, and neonatal complications. Statistical analysis was performed using chi-square and -tests for comparisons between groups.
A total of 400 women were enrolled, with 200 in each group. The mean induction-to-delivery interval was significantly shorter in the 50 μg group ( = 0.001). Uterine tachysystole and postpartum hemorrhage due to atonia were more frequent in the 25 μg group ( < 0.05). The rates of cesarean and instrumental deliveries did not differ significantly between groups. The mean ± SD age was 27.1 ± 5.27 years in the 25 μg group and 26.8 ± 5.11 years in the 50 μg group ( = 0.639).
Both dosing regimens of oral misoprostol were effective for labor induction, but the 50 μg dose was associated with a shorter induction-to-delivery time. The findings suggest that adjusting the misoprostol dosage may reduce complications. IRCT20221123056587N1.
口服米索前列醇用于引产的推荐给药方案包括每2小时25μg和每4小时50μg。然而,在沙希德·阿克巴拉巴迪医院,这些方案没有具体的规程。本研究旨在评估两种给药方案用于胎膜早破(PROM)孕妇引产的安全性和有效性,并制定一个定制规程以尽量减少母婴并发症。
这项随机对照试验于2021年至2023年在沙希德·阿克巴拉巴迪医院进行,纳入足月单胎妊娠且确诊为胎膜早破的孕妇。参与者被随机分配接受每2小时口服25μg米索前列醇(最多12剂)或每小时50μg(最多6剂)。主要结局是分娩方式。次要结局包括引产至分娩时间、子宫收缩过速、产后出血和新生儿并发症。使用卡方检验和t检验进行组间比较统计分析。
共纳入400名女性,每组200名。50μg组的平均引产至分娩间隔明显更短(P = 0.001)。25μg组子宫收缩过速和因宫缩乏力导致的产后出血更频繁(P < 0.05)。两组剖宫产和器械助产率无显著差异。25μg组的平均年龄±标准差为27.1±5.27岁,50μg组为26.8±5.11岁(P = 0.639)。
两种口服米索前列醇给药方案均对引产有效,但50μg剂量与较短的引产至分娩时间相关。研究结果表明,调整米索前列醇剂量可能减少并发症。IRCT20221123056587N1。